Adial Pharmaceuticals Inc
ADIL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.34M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $23.34 Million |
|---|---|
| Enterprise Value | $-5,372,238.00 |
| Earnings per Share | $-11.93 |
| Beta | 1.5 |
| Outstanding Shares | 4,621,735 |
Return
| Return on Equity | 150.61% |
|---|---|
| Return on Assets | -198.70% |
| Return on Invested Capital | -240.64% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.27 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-1.03
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.17
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.28%▼ 18.42% |
|---|---|
| Total Invested | $53,161▼ 97.23% |
| Investors Holding | 3▼ 15.00% |
About Adial Pharmaceuticals Inc
2,018 employees
CEO: Cary J. Claiborne
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.